google-site-verification: googlec7193c3de77668c9.html

Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks

[
New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine.


Source link

Advertisements

See also  Ghana collects half the blood it needs—digital approaches can improve that

Check Also

Europe's endocrine community calls for policy action as growing demand puts hormone health workforce under pressure

[ The Prague Declaration and accompanying white paper, “Endocrine Workforce 2026: Recommendations for a Healthier …

Aortic structure may affect midlife rise in pulse pressure, aortic stiffness in women

[ Credit: Unsplash/CC0 Public Domain Contradicting conventional wisdom, menopause may not be the driving force …

Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation

[ Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) …

Leave a Reply

Available for Amazon Prime